News

Under the contract, the companies will work on drug metabolism and pharmacokinetics studies, including CYP inhibition, metabolic identification and stability. It will also include metabolic identification and stability,

Initially, the company will get around $17m over 18 months from BARDA to ramp up the development of HemaMax. Additional financing over the next 3.5 years is available

Hartmanis held leadership positions in Gambro, Amersham and Pharmacia and was appointed as CEO of the specialty pharmaceutical company BioPhausia in 2010. Medivir chairman of the board Goran

The filing of the application is backed by the results of a double-blind study (Hopeful1 Study) which included around 334 rheumatoid arthritis patients and received concomitant treatment using

The approval was granted on the basis of the results of a domestic phase II clinical trial and overseas phase III clinical trials. The results from the overseas

The results from a Phase III trial showed with weekly subcutaneous injections for 72 weeks, Teribone helps in decreasing the risk of developing new vertebral fracture by 78.6%

The results from a Phase II Saphire study investigating resminostat as a third-line treatment in relapsed/refractory HL patients, showed a 33.3% overall response rate and 54.5% of patients

The new EHR enables the US healthcare practitioners to document clinical notes, schedule office visits, and bill for medical services, without any vendor lock in. The Phyaura community

The study compared trastuzumab emtansine to standard treatment with Herceptin (trastuzumab) plus docetaxel chemotherapy. The results of the trial suggested that the patients who were given trastuzumab emtansine